Cytogen Corp said its will
expand clinical trials of its cancer imaging technology. It
said the new studies were anticipated to begin by mid year.
    It said the first phase of human testing begain in October.
The technology uses a monocloncal antibody tagged with a
radioisotope to diagnose colorectal cancer and several
other cancer types. It said preliminary studies revealed the
antibody combination was well tolerated in the patients
studied.
 Reuter
&#3;